Publications

J. Hong, H.T. Borno, O. Harismendy, S. Yousefi, P. Cinar, H.S. Rugo, M-O. Kim, V.S. Koshkin, A. Bailey, R.R. McKay, E.J. Small. 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium. Annals of Oncology. 2021. PMID:

Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao SG. Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. NPJ genomic medicine. 2021. PMID: 34548481

Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. The oncologist. 2021. PMID: 34506673

Tempero M. Targeting KRAS: Good, But Is It Good Enough? Journal of the National Comprehensive Cancer Network : JNCCN. 2021. PMID: 34551387

Camargo JF, Ebisu Y, Jimenez-Jimenez A, Natori Y, Moroz I, Morris MI, Alencar M, Anderson AD, Lekakis L, Beitinjaneh A, Goodman M, Wang T, Pereira D, Komanduri KV. Lower Incidence of Cytomegalovirus Reactivation Following Post-Transplantation Cyclophosphamide HLA-Mismatched Unrelated Donor Transplantation. Transplantation and cellular therapy. 2021. PMID: 34543769

Vellanki PJ, DeBoy EA, Bawadkji MM, Schuchter L, Rooper L, Mehra R, Kang H, Armanios M. Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations. JCO precision oncology. 2021. PMID: 34568721

Mouhieddine TH, Hieulle J, Moshier E, Richard S, Richter J, Cho HJ, Parekh S, Barlogie B, Chari A, Jagannath S, Madduri D. Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2021. PMID: 34670732

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. The Lancet. Oncology. 2021. PMID: 34516954

Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, de Abreu Alves F, Ashbury FD, Eng L, Fitch M, Jain H, Jefford M, Klemanski D, Koczwara B, Loh K, Prasad M, Rugo H, Soto-Perez-de-Celis E, van den Hurk C, Chan A, Multinational Association of Supportive Care in Cancer (MASCC) Survivorship Study Group. The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. Annals of oncology : official journal of the European Society for Medical Oncology. 2021. PMID: 34509615

Hu K, Ghandi M, Huang FW. Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines. eLife. 2021. PMID: 34486523

Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ breast cancer. 2021. PMID: 34489453

Kelley RK, Joseph NM, Nimeiri HS, Hwang J, Kulik LM, Ngo Z, Behr SC, Onodera C, Zhang K, Bocobo AG, Benson AB, Venook AP, Gordan JD. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver cancer. 2021. PMID: 34950179

Borno HT, Lin TK, Zhang S, Skafel A, Lalanne A, Dornsife D, Johnson R, Spicer D, Small EJ, Rhoads KF. Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. Journal of Cancer Policy. 2021. PMID: 35559801

Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Schlotter S, Pearson R, Kitzler R, Mozhenkova A, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD, Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Lozanski G, Baiocchi RA. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. Volume 12 Frontiers in immunology. 2021. PMID: 34539628

Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Central Science. 2021. PMID: 34729407

James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical pharmacokinetics. 2021. PMID: 34297319

Alexander E Perl, Jessica K Altman, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Catherine C Smith, Mark J Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu. Poster: AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Clinical Lymphoma Myeloma & Leukemia. 2021. PMID:

Jessica K. Altman, Naval Daver, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James McCloskey, Catherine C. Smith, Gary Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Satya Siddani, Jing Wang, Paul Lee, Alexander E. Perl. Poster: AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study. Clinical Lymphoma Myeloma & Leukemia. 2021. PMID:

R. Aggarwal, S. Umetsu, M. Dhawan, J. Grabowsky, J. Carnevale, M. Howell, L. Wilch, J. Chapman, E. Alvarez, S. Calabrese, S. Smith, N. Shah, E. Dean, P. Munster, E. Collisson. 512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies. Annals of Oncology. 2021. PMID:

Dickerson JC, Ibeka P, Inoyo I, Oke OO, Adewuyi SA, Barry D, Bello A, Fasawe O, Garrity P, Habeebu M, Huang FW, Mulema V, Nwankwo KC, Remen D, Wiwa O, Bhatt AS, Roy M. Implementing Patient-Directed Cancer Education Materials Across Nigeria. JCO global oncology. 2021. PMID: 34860566